Contact

Our portfolio

Primagen

Primagen Holding focuses on developing molecular diagnostic tests and investing in bio- and medtech startups. The company generates revenues through the licensing of their diagnostics technology. Primagen Holding’s portfolio includes investments in PulseCath and Akkolens International.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Infectious Disease
  • Founding year: 1993
Visit website

Want to get in contact about Primagen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Fermioniq
Combining quantum computing and classical simulations for material science.
SusPhos
Upcycling phosphate waste into sustainable industrial products.
ForceSense
Improving surgical skill development with the Lapron Boxtrainer, a laparoscopic training system.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Fermioniq
Combining quantum computing and classical simulations for material science.
SusPhos
Upcycling phosphate waste into sustainable industrial products.
ForceSense
Improving surgical skill development with the Lapron Boxtrainer, a laparoscopic training system.
Explore full AAV portfolio
Contact